vs

Side-by-side financial comparison of DigitalOcean Holdings, Inc. (DOCN) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.

DigitalOcean Holdings, Inc. is the larger business by last-quarter revenue ($242.4M vs $196.9M, roughly 1.2× Pacira BioSciences, Inc.). On growth, DigitalOcean Holdings, Inc. posted the faster year-over-year revenue change (18.3% vs 5.1%). Pacira BioSciences, Inc. produced more free cash flow last quarter ($43.5M vs $31.1M). Over the past eight quarters, DigitalOcean Holdings, Inc.'s revenue compounded faster (14.5% CAGR vs 8.5%).

DigitalOcean Holdings, Inc. is an American multinational technology company and cloud service provider. The company is headquartered in Broomfield, Colorado, US, with 15 globally distributed data centers. DigitalOcean provides developers, startups, and SMBs with cloud infrastructure-as-a-service platforms.

Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.

DOCN vs PCRX — Head-to-Head

Bigger by revenue
DOCN
DOCN
1.2× larger
DOCN
$242.4M
$196.9M
PCRX
Growing faster (revenue YoY)
DOCN
DOCN
+13.1% gap
DOCN
18.3%
5.1%
PCRX
More free cash flow
PCRX
PCRX
$12.3M more FCF
PCRX
$43.5M
$31.1M
DOCN
Faster 2-yr revenue CAGR
DOCN
DOCN
Annualised
DOCN
14.5%
8.5%
PCRX

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
DOCN
DOCN
PCRX
PCRX
Revenue
$242.4M
$196.9M
Net Profit
$25.7M
Gross Margin
58.7%
79.5%
Operating Margin
16.0%
1.2%
Net Margin
10.6%
Revenue YoY
18.3%
5.1%
Net Profit YoY
40.5%
EPS (diluted)
$0.23
$0.05

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
DOCN
DOCN
PCRX
PCRX
Q4 25
$242.4M
$196.9M
Q3 25
$229.6M
$179.5M
Q2 25
$218.7M
$181.1M
Q1 25
$210.7M
$168.9M
Q4 24
$204.9M
$187.3M
Q3 24
$198.5M
$168.6M
Q2 24
$192.5M
$178.0M
Q1 24
$184.7M
$167.1M
Net Profit
DOCN
DOCN
PCRX
PCRX
Q4 25
$25.7M
Q3 25
$158.4M
$5.4M
Q2 25
$37.0M
$-4.8M
Q1 25
$38.2M
$4.8M
Q4 24
$18.3M
Q3 24
$32.9M
$-143.5M
Q2 24
$19.1M
$18.9M
Q1 24
$14.1M
$9.0M
Gross Margin
DOCN
DOCN
PCRX
PCRX
Q4 25
58.7%
79.5%
Q3 25
59.6%
80.9%
Q2 25
59.9%
77.4%
Q1 25
61.4%
79.7%
Q4 24
57.1%
78.7%
Q3 24
60.2%
76.9%
Q2 24
61.0%
75.1%
Q1 24
60.7%
71.6%
Operating Margin
DOCN
DOCN
PCRX
PCRX
Q4 25
16.0%
1.2%
Q3 25
19.6%
3.5%
Q2 25
16.3%
4.7%
Q1 25
17.9%
1.2%
Q4 24
15.9%
13.2%
Q3 24
12.4%
-82.8%
Q2 24
11.6%
15.9%
Q1 24
6.2%
7.9%
Net Margin
DOCN
DOCN
PCRX
PCRX
Q4 25
10.6%
Q3 25
69.0%
3.0%
Q2 25
16.9%
-2.7%
Q1 25
18.1%
2.8%
Q4 24
8.9%
Q3 24
16.6%
-85.1%
Q2 24
9.9%
10.6%
Q1 24
7.7%
5.4%
EPS (diluted)
DOCN
DOCN
PCRX
PCRX
Q4 25
$0.23
$0.05
Q3 25
$1.51
$0.12
Q2 25
$0.39
$-0.11
Q1 25
$0.39
$0.10
Q4 24
$0.21
$0.38
Q3 24
$0.33
$-3.11
Q2 24
$0.20
$0.39
Q1 24
$0.15
$0.19

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
DOCN
DOCN
PCRX
PCRX
Cash + ST InvestmentsLiquidity on hand
$254.5M
$238.4M
Total DebtLower is stronger
$1.3B
$372.2M
Stockholders' EquityBook value
$-28.7M
$693.1M
Total Assets
$1.8B
$1.3B
Debt / EquityLower = less leverage
0.54×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
DOCN
DOCN
PCRX
PCRX
Q4 25
$254.5M
$238.4M
Q3 25
$236.6M
$246.3M
Q2 25
$387.7M
$445.9M
Q1 25
$360.4M
$493.6M
Q4 24
$428.4M
$484.6M
Q3 24
$439.9M
$453.8M
Q2 24
$443.1M
$404.2M
Q1 24
$419.1M
$325.9M
Total Debt
DOCN
DOCN
PCRX
PCRX
Q4 25
$1.3B
$372.2M
Q3 25
$1.3B
$376.7M
Q2 25
$580.5M
Q1 25
$583.4M
Q4 24
$1.5B
$585.3M
Q3 24
Q2 24
Q1 24
Stockholders' Equity
DOCN
DOCN
PCRX
PCRX
Q4 25
$-28.7M
$693.1M
Q3 25
$-69.6M
$727.2M
Q2 25
$-175.2M
$757.8M
Q1 25
$-210.7M
$798.5M
Q4 24
$-203.0M
$778.3M
Q3 24
$-211.7M
$749.6M
Q2 24
$-253.8M
$879.3M
Q1 24
$-286.1M
$892.2M
Total Assets
DOCN
DOCN
PCRX
PCRX
Q4 25
$1.8B
$1.3B
Q3 25
$1.7B
$1.3B
Q2 25
$1.7B
$1.5B
Q1 25
$1.6B
$1.6B
Q4 24
$1.6B
$1.6B
Q3 24
$1.5B
$1.5B
Q2 24
$1.5B
$1.6B
Q1 24
$1.5B
$1.6B
Debt / Equity
DOCN
DOCN
PCRX
PCRX
Q4 25
0.54×
Q3 25
0.52×
Q2 25
0.77×
Q1 25
0.73×
Q4 24
0.75×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
DOCN
DOCN
PCRX
PCRX
Operating Cash FlowLast quarter
$57.3M
$43.7M
Free Cash FlowOCF − Capex
$31.1M
$43.5M
FCF MarginFCF / Revenue
12.8%
22.1%
Capex IntensityCapex / Revenue
10.8%
0.1%
Cash ConversionOCF / Net Profit
2.23×
TTM Free Cash FlowTrailing 4 quarters
$180.5M
$136.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
DOCN
DOCN
PCRX
PCRX
Q4 25
$57.3M
$43.7M
Q3 25
$95.8M
$60.8M
Q2 25
$92.4M
$12.0M
Q1 25
$64.1M
$35.5M
Q4 24
$71.3M
$33.1M
Q3 24
$73.4M
$53.9M
Q2 24
$71.3M
$53.2M
Q1 24
$66.7M
$49.1M
Free Cash Flow
DOCN
DOCN
PCRX
PCRX
Q4 25
$31.1M
$43.5M
Q3 25
$88.0M
$57.0M
Q2 25
$59.3M
$9.3M
Q1 25
$2.1M
$26.9M
Q4 24
$26.1M
$31.0M
Q3 24
$16.0M
$49.8M
Q2 24
$39.5M
$51.6M
Q1 24
$23.0M
$46.3M
FCF Margin
DOCN
DOCN
PCRX
PCRX
Q4 25
12.8%
22.1%
Q3 25
38.3%
31.7%
Q2 25
27.1%
5.1%
Q1 25
1.0%
15.9%
Q4 24
12.7%
16.6%
Q3 24
8.1%
29.6%
Q2 24
20.5%
29.0%
Q1 24
12.5%
27.7%
Capex Intensity
DOCN
DOCN
PCRX
PCRX
Q4 25
10.8%
0.1%
Q3 25
3.4%
2.2%
Q2 25
15.2%
1.5%
Q1 25
29.4%
5.1%
Q4 24
22.1%
1.1%
Q3 24
28.9%
2.4%
Q2 24
16.6%
0.9%
Q1 24
23.6%
1.7%
Cash Conversion
DOCN
DOCN
PCRX
PCRX
Q4 25
2.23×
Q3 25
0.60×
11.20×
Q2 25
2.50×
Q1 25
1.68×
7.37×
Q4 24
3.91×
Q3 24
2.23×
Q2 24
3.73×
2.82×
Q1 24
4.72×
5.47×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

DOCN
DOCN

Scalers$84.3M35%
Scalers Plus$69.9M29%
Builders$64.1M26%
Learners Testers And Other$24.1M10%

PCRX
PCRX

EXPAREL$155.8M79%
ZILRETTA$33.0M17%
Iovera$7.0M4%

Related Comparisons